Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
What is your preferred chemotherapy regimen to give concurrently with radiation for unresectable stage 3 NSCLC?
What factors do you use to decide between weekly low-dose carboplatin and paclitaxel combination vs cisplatin based doublet, and do you routinelty use consolidation chemotherapy when you give weekly carbo/taxol?
Answer from: Medical Oncologist at Academic Institution
I have generally preferred the cisplatin/etoposide regimen, in part due to the "consolidation" portion of the weekly paclitaxel/carboplatin regimen (ie in patients who could tolerate cisplatin based regimen, it seems preferable to be done after six weeks rather than 12 weeks). That being said, I do ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I prefer the regimen of weekly low dose carboplatin (AUC = 2) and paclitaxel (45-50 mg/m2) x 6 with concurrent radiotherapy to 60 Gy followed by two cycles of consolidation carboplatin (AUC = 5-6), paclitaxel (200 mg/m2). This regimen has been extensively employed. The results of the RTOG 0617 trial...
Answer from: Medical Oncologist at Community Practice
If possible, I use cisplatin and etoposide. If no progression, add durvalumab subsequently. Having said that, if a patient's renal function or KPS are an issue then I have used weekly carbo taxol. I discuss two cycles of consolidation and then add durvalumab if no progression.
Answer from: Medical Oncologist at Community Practice
There is a discussion about this topic in the era of PACIFIC which can be found here.